“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

Immunovia and
IMMray™ technology
(10 min)

Financial reports

April 2018

Immunovia AB published the company’s Interim Report January-March 2018 on Friday, April 27, 2018, at 08:00 a.m. CET.

Financial reports


24 August, 2018
Interim Report 1 Jan – 30 June 2018
Place: Immunovia
6 September, 2018
CEO Mats Grahn presents at Paretos “9th Annual Health Care Conference”, Stockholm
Place: Stockholm, Sweden
10-11 September, 2018
EIC Innovators’ Summit 2018
Place: Berlin, Germany
All events

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports